Senior Vice President, General Manager Europe
Vice President, Value and Access
Vice President and General Counsel, International
Executive Director, Human Resources
Executive Director, Compliance
Director, Corporate Affairs
Vice President, Medical Affairs
Executive Director, Supply Chain
Vice President, Regulatory Affairs
Executive Director, Finance
Director, Information Systems
Interim General Manager United Kingdom and Ireland
Vice President and General Manager Germany
General Manager Spain
Vice President and General Manager France
General Manager Italy
Executive Director, North-East Europe Region
Vice President and General Manager, Europe Mid-Size Markets Region
Gilles Marrache is senior vice president, regional general manager, Europe. Prior to this role, Gilles served as senior vice president, regional general manager, Intercontinental, responsible for commercial operations in more than 35 countries, including Argentina, Brazil, Canada, Colombia, Mexico, South Africa and Turkey, as well as the Middle East. Previously, Gilles was vice president, Global Marketing Therapeutic Area Head for cardiovascular and neurosciences.
Gilles joined Amgen in 2002 as a business unit manager in France, before becoming General Manager of Amgen’s affiliate in Belgium and Luxembourg for two years. In 2007, he was appointed vice president, General Manager in France. In 2011, Gilles became vice president, Marketing and Business Operations for Amgen International based in Zug, Switzerland.
Prior to joining Amgen, Gilles held a variety of sales, marketing, key account and business unit leadership positions at Novartis. Gilles holds a Doctorate of Pharmacy from Paris XI University and an MBA from the Institut Supérieur du Commerce (ISC).
Gavin Lewis is Amgen’s VP Value, Access & Policy based at the company’s European Hub in Switzerland.
Gavin originally was an undergraduate in Economics and Politics, before working for the Scottish Government as an Economist in the Health Department. After obtaining an MSc in Health Economics from York University, he joined the Pharmaceutical industry for Roche in the UK where he worked for over 10 years developing and leading their Health Economics and Pricing department.
Gavin has experience in leading over 50 Health Technology appraisals and contributed to the development of the NICE Guide to Methods for Technology Appraisal. In 2012 Gavin transferred to Basel to start a new role for Roche as Head of Pricing and Market Access for Region Europe, where he has developed a new team with responsibilities for strategic pricing, payer marketing and real world evidence for Europe. Gavin was then Global Head of Market Access for Oncology at AstraZeneca from 2015-17, before joining Amgen.
Robert Sexton is Vice President & General Counsel, International, based at Amgen’s International Headquarters in Rotkreuz, Switzerland. He manages the International Legal Group (consisting of over 40 people located throughout the major markets of EMEA, Latin America and Canada) and has responsibility for legal matters for Amgen in all countries outside the United States and the Asia Pacific Region.
Robert joined Amgen in March 2005 and has been a member of the Amgen International Management Committee and its successor committees since that time. He has played a leading role in Amgen’s international expansion into over 30 new markets. Most notably, he led Amgen’s acquisitions of Bergamo in Brazil in 2011 and Mustafa Nevzat in Turkey in 2012, as well as Amgen’s acquisition and partnering strategy in Russia, Turkey, Greece and other countries.
Robert has 30 years of experience in international legal practice in New York, Washington, DC, London, Moscow, Paris and Switzerland. Prior to joining Amgen, he spent 20 years at major international law firms in the United States and Europe.
Robert has extensive experience in life sciences compliance matters and was a primary architect of the Amgen Foreign Corrupt Practices Act (anti-corruption) Policy in 2006 and of the revised Competition Law Policy in 2008. Robert also has broad experience in life sciences mergers and acquisitions (M&A), co-promotion, co-marketing and licensing transactions, biopharmaceutical IP protection, R&D and clinical trial issues and cross-border arbitration and litigation.
Robert is currently listed in the Legal 500 “GC Powerlist for Switzerland” (i.e., top 100 GCs in the country) and his team, the International Legal Group, is currently listed on the Legal 500 “In-House Teams Powerlist.
Robert is fluent in English, Russian and French and also speaks German, Spanish, and Italian. He received his Bachelor of Arts, with High Distinction, and Master of Arts from the University of Virginia, and his J.D., summa cum laude, from the Catholic University of America Law School.
Michael Egermann is the human resources lead for Amgen’s European region. Prior to this role, he was the human resources lead for Amgen’s global corporate functions based in the Global headquarters in the United States.
Michael joined Amgen in 2006 as human resources director Germany. He then held regional human resources roles in Amgen’s European and International organizations. Prior to joining Amgen, Michael held human resources business partner and specialist roles at Mead Johnson Nutritionals and Bristol-Myers Squibb based in the United States and Asia.
Michael holds a Master's degree in Psychology from the University of Vienna (Austria), with a specialization in Industrial and Organizational Psychology. He also holds a Master's degree in Human Resources and Industrial Relations from the University of Minnesota (USA).
Sharmeen Khan is the Executive Director of Compliance for Europe. Prior to taking this role, Sharmeen was managing the Compliance function in Amgen’s Turkey, Middle East and Africa markets.
Sharmeen joined Amgen in 2014 and has worked and lived in Dubai and Istanbul for Amgen. Prior to joining Amgen she worked as a lawyer, and as a compliance investigations Lead for Pfizer for Africa and Middle East and some Asian Markets. Sharmeen has a Master of Laws (focus on International Criminal Law) from University of Sussex.
Emma Gilbert is corporate affairs director for Europe with responsibility for corporate communications and patient advocacy. Prior to the European role, Emma served as the corporate affairs lead for the UK and Ireland. Emma also led local Amgen Foundation initiatives, including the Amgen Biotech Experience and Amgen Scholars, highlighting Amgen’s commitment to science education in the UK.
Prior to joining Amgen in 2009, Emma spent over 20 years at leading healthcare communications agencies in the UK.
Emma has a BA (Hons) in Communication Studies from the University of Nottingham.
Isma Benattia, M.D., MBA, currently serves as the VP, Head of Medical Affairs Europe including the European headquarters and affiliate Medical Teams, across all therapeutic areas. Isma is very passionate about patient involvement in the Research & Development of innovative medicines, the life-cycle management of marketed products and is working extensively with various stakeholders to accelerate medication accesses.
Prior to her current role, Isma was responsible for advancing Amgen’s expertise and leadership in Global Patient Safety & Labeling. With over 20 years of pharmaceutical industry experience, she has held various roles with increasing level of responsibility in different organizations. Prior to joining Amgen, she served as Vice President and Head of Safety Surveillance and Risk Management at Sanofi Genzyme and Executive Vice President with Pfizer Consumer Health Care. She has also worked in Clinical Development, Medical Affairs and Executive Management at Wyeth Pharmaceuticals and Eli Lilly France.
Isma earned Master of Business Administration at the Massachusetts Institute of Technology Sloan School of Management and a Master in Bioethics from the University of Pennsylvania. Isma Benattia received her medical degree from Faculte de Medecine d’Alger and Faculte de Medecine Pitié-Salpêtrière University Hospital (Faculty Pierre et Marie Curie).
Carlos Garcia is Executive Director of Supply Chain for the European Region. Prior to this, Carlos was the Executive Director of Supply Chain for the Intercontinental Region which includes Latin America, Canada, Middle East, Africa and Turkey. He was also responsible for the Global Supply Chain Hubs located in Breda and Puerto Rico managing all outbound shipments from manufacturing sites to all Regions.
With over 25 years of experience in the pharmaceutical industry, Carlos has held various key positions such as Executive Director Global Distribution, Executive Director Risk Management, Executive Director Site Supply Chain, Packaging Operations Director, Manufacturing Operations Director, and Engineering and Maintenance Team Leader.
Carlos’ experience is global in nature having worked in Puerto Rico, USA, and Europe and with extensive experience in the Intercontinental region.
Carlos holds a Bachelor’s degree in Mechanical Engineering from Texas Tech University and a Master of Business Administration from Butler University. He is also APICS CPIM certified (certified in production and inventory management).
Chris is the Head of Regulatory Affairs for Europe, co-lead of R&D for Europe and the Head of R&D for the UK Sites
As European Regulatory Affairs Head, Chris leads the team that develop and execute the regulatory strategy for Amgen’s portfolio across the European region including Russia, CIS and Israel. He ensures the efficient execution of the strategy, engagement with the regulatory agencies across Europe, and ensures the team influence the regulated environment in which Amgen operates. The European HQ and Affiliate regulatory organizations report to Chris and he is accountable for the CMC, labelling and R&D policy teams.
Chris is the co-lead for R&D in Europe and is an internal and external voice of Amgen for R&D in the region. Chris collaborates closely with the Medical R&D co-lead and together they contribute to the advancement of Amgen’s portfolio and shaping of the European framework for Medicines for the benefit of European patients.
As Head of R&D for the UK sites Chris leads the engagement of the UK based R&D team of over 500 staff across both Cambridge & Uxbridge. This role involves a close partnership with the head of the UK & Ireland Affiliate and the Global R&D leadership network.
Since joining Amgen in 2005 Chris has held several regulatory roles within Amgen based in the UK. Prior to joining Amgen Chris held both Regulatory and Research roles at BPL, who focus on medicinal products derived from human plasma. Chris holds a BSc in Biological Sciences and an MSc in Regulatory Affairs.
Adam Elinoff is the finance lead for Amgen’s European region. Prior to assuming this role, he led Amgen’s Corporate FP&A team based in the global headquarters in the United States.
Adam joined Amgen in 2006 and has held a variety of different leadership roles across finance, strategy, and business transformation. Of particular note, Adam led the project that established the Amgen Capability Center in Tampa, Florida.
Adam received his Bachelors of Arts in Economics from Hamilton College and his Master’s Degree in Business Administration (Finance) from the W.P. Carey School of Business at Arizona State University.
Roman is vice president and general manager, Germany. Prior to this role, Stampfli served as Managing Director in Spain / Portugal and in Amgen's Swiss subsidiary.
Roman has been with Amgen since 2004 and has held several different roles in the medical and commercial area, including Medical Director, Business Unit head Oncology and Regional Brand Lead.
Roman holds a doctor in Medicine from the University of Bern and an EMBA from the University of Zurich.
Fina Lladós is the Amgen Iberia General Manager since September 2017 and a member of the company's management committee since 2009.
Fina holds a degree in Pharmacy from the University of Barcelona, a Management Development Program from IESE, a postgraduate degree in Industrial Medicine from the UAB, and a Master's Degree in the Pharmaceutical Industry from CESIF. Fina has developed a professional career of more than twenty-five years in the pharmaceutical industry. After her job in Roche and Sanofi-Aventis, she joined Amgen. Over these 20 years in Amgen she has worked in Spain and Switzerland, where the company has its European headquarters.
Fina has held various positions of responsibility at Amgen in the R&D, medical and commercial areas and in different therapeutic areas ranging from Clinical Development in early stages, to leadership positions in the Medical Department, as well as Business Directions in different areas before her role as a General Manager.
She currently sits on the Board of Directors of Farmaindustria, of which she is also a member of its Governing Council, and currently holds one of the Vice Presidencies of LAWG. Moreover, she is a member of the Board of Directors of the U.S. Chamber of Commerce in Spain. Moreover, she is participating in the ‘Mujeres de la Sanidad’ initiative to foster the female leadership and talent in the health field.
Corinne Blachier-Poisson is a graduate of HEC and holds a master's degree in international economics from the University of Paris-Dauphine.
She was responsible for the medico-economic evaluation at AFSSAPS between 1998 and 2002. After holding various organizational and marketing/sales positions at Rhône-Poulenc and Novartis, Corinne Blachier-Poisson joined Amgen France in 2009 where she has held several positions, first as business unit lead Nephrology, then Executive Director of the Oncology/Hematology Business Unit in 2011, and Executive Director of Value, Access & Policy lead in 2013. She then joined Amgen's headquarter in the Thousand-Oaks (California) on a mission dedicated to the Group's transformation, before being appointed Chief Executive Officer of Amgen Belgium and Luxembourg in 2016, a position she had held until January 1, 2019 when she has been appointed Vice President and General Manager of Amgen France.
Today President of the largest affiliate of Amgen in Europe, Corinne is responsible for coordinating actions, and supporting its 380 employees in their missions.
She is also member of the Board of Directors of the LEEM.
Soren Giese – President and CEO of Amgen in Italy since July 2019 – is a manager with solid international experience.
He joined Amgen in 2016, holding the position of Executive Director, Commercial Operations & Business Strategy of the Intercontinental Region for the American biotechnology group, operating in the markets of Latin America, including in particular that of Colombia, a Country where he was also General Manager.
Before joining Amgen, Soren worked for several years at Bristol-Myers Squibb, a pharmaceutical company where he was entrusted with positions of increasing responsibility, which he carried out in several Countries of the world: from the United States to Mexico and, finally, to Russia, where he was General Manager.
German-born, Soren has a degree in chemistry, as well as an MBA in marketing achieved in the United States.
Based in Rotkreuz, Victoria Anashkina is Amgen’s Executive Director for the North/East Region and part of the European Management Committee since October 2014.
Victoria is Medical Doctor by education. She holds Master Degree in Consulting and Coaching for Change from INSEAD (Fr) and Marketing Diploma of the Chartered Institute of Marketing (UK).
After graduating from the medical institute in 1989 Victoria worked as a medical doctor. In 1993 she began her career in the Russian Pharmaceutical market as a medical representative.
Victoria has rich experience in pharma market from 1993 till 2006 she has taken different management positions in Zeneca Pharmaceuticals, AstraZeneca UK LTD and Polpharma mainly in the field of marketing, business development and general management.
From 2006 till 2014 Victoria was Head of Amgen Russia.
John joined Amgen in March 2007 and is currently the VP and Regional General Manager for Amgen’s business in our mid-sized markets region comprising Austria, Belgium, Greece, The Netherlands, The Nordic and Baltic countries and Switzerland. Previously he was General Manager for Amgen in the UK and Ireland. He has almost 40 years’ experience in the Biopharmaceutical sector having worked for both Glaxo and Pfizer prior to Amgen in roles in the UK, Europe and Africa.
John has held a number of Industry Association roles across a number of countries. He was President of the South African Industry Association (IMSA) from 2003 to 2005. He was Chairman of the American Pharmaceutical Group (APG) in the UK between 2012 and 2014, representing the 10 major US inward investors in the sector. He was a Board member of the Association of the British Pharmaceutical Industry (ABPI) from 2008 until 2018 and was the ABPI President from 2015 to 2017.
John graduated from the University of Durham in the United Kingdom with a BA (hons) in Economics.
Claudio Onodera is Amgen’s Director, Information Systems based at the European Hub in Switzerland.
Claudio joined Amgen in 2015, with 25 years' experience and an extensive background in technology, enterprise architecture, software development and consulting. Prior to his current role, Claudio led the IS Product Promotion team in Europe, responsible for all Multichannel IS platforms supporting sales and marketing enabling Amgen’s customer engagement strategy in the region.
Claudio started his career in Brazil and held multiple IS leadership roles in Syngenta, Deloitte Consulting, Siebel Systems and Baan Company. He relocated to Switzerland in 2006, holds a bachelor’s degree in Physics from the University of Sao Paulo, with specialization in nuclear reactor security systems and computer simulation software.